A Deep Dive Into the FDA's Psychedelic Clinical Research Guidelines


Decoding FDA Requirements

Navigating the unique attributes of psychedelic drug development

Watch as Altasciences’ panel of experts discuss the FDA’s recently published guidelines for early-phase clinical development of psychedelics and the assessment of abuse potential.


Topics covered:
      •   important FDA recommendations;
      •   clinical methods to optimize early-phase clinical trials with psychedelics;
      •   how to address the abuse potential evaluation requirement for psychedelic drugs; and
      •   strategies to ensure study integrity.



You may also be interested in the following resources:
      •   Webpage: CNS Drug Development Solutions
      •   Scientific Journal: Challenges Associated with Schedule I Therapeutic Development
      •   Webinar: Practical Approaches to Conducting Early Clinical Trials with Psychedelics